Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03915366Phase 2Completed

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

Role: collaborator

NCT03226379Not ApplicableCompleted

Driving Reduced AIDS-associated Meningo-encephalitis Mortality

Role: collaborator

NCT02960919Completed

Innovative Treatments in Pneumonia (ITIP) 3

Role: collaborator

NCT03724214Not ApplicableUnknown

Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa

Role: collaborator

NCT03185637Completed

Children's Surgery in Sub-Saharan Africa

Role: collaborator

NCT00164736Phase 3Completed

Breastfeeding, Antiretroviral, and Nutrition Study

Role: collaborator

NCT00164762Completed

Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers

Role: collaborator

All 7 trials loaded